Inventor · disambiguated record
Guoliang Xun
Also filed as: XUN GUOLIANG
7 granted patents·6 pending applications·21 citations·filing 2010–2025
79Inventor score
Top patents by PatentIndex Score
13 records- 0192US11420970B1Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agentsNOVARTIS AG·Filed 2021·Granted Aug 23, 2022·5 cites·29 claims
- 0286US12312353B2Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agentsNOVARTIS AG·Filed 2022·Granted May 27, 2025·1 cites·20 claims
- 0383US8410264B2Heterocyclic oxime compoundsDAI MIAO·Filed 2010·Granted Apr 2, 2013·9 cites·17 claims
- 0476US8497368B2Heterocyclic hydrazone compoundsHE FENG·Filed 2010·Granted Jul 30, 2013·4 cites·18 claims
- 0572US2025276971A1Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agentsNOVARTIS AG·Filed 2025·Application pending·0 cites
- 0671US8507676B2Heterocyclic oxime compoundsDAI MIAO·Filed 2012·Granted Aug 13, 2013·2 cites·15 claims
- 0755US2025382621A1Immune effector cell therapies with enhanced efficacyNOVARTIS AG·Filed 2025·Application pending·0 cites
- 0853US2024101573A1Macrocyclic k-ras g12c inhibitor, preparation method therefor and use thereofABBISKO THERAPEUTICS CO LTD·Filed 2021·Application pending·0 cites
- 0950US2022009894A11,2,3,4-tetrahydroquinoxaline derivative, preparation method therefor and application thereofABBISKO THERAPEUTICS CO LTD·Filed 2019·Application pending·0 cites
- 1045US2019000880A1Immune effector cell therapies with enhanced efficacyMOTZ GREGORY·Filed 2016·Application pending·0 cites
- 1137US10604502B2Substituted 5-cyanoindole compounds and uses thereofNOVARTIS AG·Filed 2018·Granted Mar 31, 2020·0 cites·18 claims
- 1235US10590079B2Cyano-substituted indoles as LSD1 inhibitorsNOVARTIS AG·Filed 2017·Granted Mar 17, 2020·0 cites·16 claims
- 1335US2019298715A1Immune effector cell therapies with enhanced efficacyMOTZ GREGORY·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Guoliang Xun files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →